Literature DB >> 24267634

Subcutaneous DMPA: a better lower dose approach.

James D Shelton1, Vera Halpern2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24267634     DOI： 10.1016/j.contraception.2013.10.010

Source DB:  PubMed          Journal:  Contraception        ISSN： 0010-7824            Impact factor:   3.375


× No keyword cloud information.
  10 in total

1.  HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.

Authors:  Renee Heffron; Randy Stalter; Maria Pyra; Kavita Nanda; David W Erikson; Florian Hladik; Steven W Blue; Nicole L Davis; Nelly Mugo; Athena P Kourtis; Jairam R Lingappa; Jared M Baeten
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

2.  Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion.

Authors:  Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Kristen M Aceves; Angelo Torres; Thomas L Cherpes
Journal:  Contraception       Date:  2019-07-11       Impact factor: 3.375

3.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

4.  The Need for Policy Change Regarding Progestin-Only Injectable Contraceptives.

Authors:  Erica L Gollub; Heidi E Jones; Lauren J Ralph; Janneke H H M van de Wijgert; Nancy Padian; Zena Stein
Journal:  J Womens Health (Larchmt)       Date:  2018-12-21       Impact factor: 3.017

Review 5.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

6.  A better future for injectable contraception?

Authors: 
Journal:  Glob Health Sci Pract       Date:  2014-11-13

7.  The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.

Authors:  Roslyn M Ray; Michelle F Maritz; Chanel Avenant; Michele Tomasicchio; Sigcinile Dlamini; Zephne van der Spuy; Janet P Hapgood
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

8.  Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women.

Authors:  Renee Heffron; Sharon L Achilles; Laneta J Dorflinger; Janet P Hapgood; James Kiarie; Chelsea B Polis; Petrus S Steyn
Journal:  Contraception       Date:  2018-12-18       Impact factor: 3.375

9.  Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate.

Authors:  Douglas J Taylor; Vera Halpern; Vivian Brache; Luis Bahamondes; Jeffrey T Jensen; Laneta J Dorflinger
Journal:  Contracept X       Date:  2022-02-23

10.  Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.

Authors:  Leo Turner; Lam P Ly; Reena Desai; Gurmeet K S Singh; Timothy D Handelsman; Sasha Savkovic; Carolyn Fennell; Veena Jayadev; Ann Conway; David J Handelsman
Journal:  J Endocr Soc       Date:  2019-06-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.